Novo Nordisk A/S (NOVOB) Earnings Call Transcripts

Novo Nordisk A/S's Latest Earnings Call - June 7, 2026

In the second quarter of fiscal year 2026, Novo Nordisk reported significant growth driven by the strong performance of its GLP-1 products, particularly the recently launched pill version of Wegovy, which has surpassed 3 million prescriptions in just 22 weeks. Revenue for the quarter reached $6.5 billion, reflecting a 15% increase year-over-year, while earnings per share (EPS) were reported at $1.20, exceeding analyst expectations. Management maintained its full-year guidance, projecting revenue growth of 12-15%, signaling confidence in continued momentum despite increasing competition in the obesity and diabetes treatment markets.

Reported metrics

Guidance from management

Novo Nordisk maintained its full-year revenue growth guidance of 12-15%, reflecting confidence in ongoing product performance and market dynamics.

What management said

So I really don't want to talk either good or bad about my competitor, but I have to disagree with you that they look similar. So I think you're correct that retatrutide showed a 1.7 percentage point reduction in A1C, but the placebo arm showed 0.8% reduction. So when you placebo correct, which we have to do as a scientist, the reduction is around 1.1, 1.2 percentage points...

Yes. All right. 1.1. Fair enough. And this is to be compared with what we've seen just with CagriSema, which is around 1.6 to 1.8 placebo-controlled. So I actually don't agree. I think the weight loss was comparable. But on glycemic control, I think CagriSema seems to stand out. And I would say the safety and tolerability profile with CagriSema also appears to be more attractive. Obviously, indirect comparisons, you ...

What analysts pressed on

Analysts expressed concerns regarding the competitive landscape, particularly with the emergence of new products in the obesity market. There were questions about how Novo Nordisk plans to maintain its market share and the implications of increasing competition on future growth.

Main topics on the call

• Strong Prescription Growth for Wegovy Pill — Novo Nordisk announced that the Wegovy pill has achieved over 3 million prescriptions in just 22 weeks, with a notable acceleration in growth, stating, "It took us 10 weeks to get to 1 million prescriptions. In the last ...
• CagriSema Efficacy and Safety Profile — Management emphasized the strong efficacy of CagriSema in type 2 diabetes, reporting a weight loss of 14.2 percentage points and a 1.9% reduction in A1c. The CEO stated, "CagriSema seems to stand out, both on efficacy an...
• Regulatory Submission Timeline — Novo Nordisk is awaiting cardiovascular outcomes data for CagriSema before proceeding with regulatory submissions, which are expected to occur next year. This was highlighted when management stated, "We are not ready to ...
• Market Competition and Positioning — Management acknowledged increasing competition in the obesity market but expressed confidence in their product differentiation, particularly the Wegovy pill's convenience. The CEO noted, "If you want convenience, then a ...

Read the full Novo Nordisk A/S transcript (June 7, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 74 Novo Nordisk A/S earnings call transcripts on record, spanning January 14, 2020 to August 5, 2026. Based on this history, Novo Nordisk A/S reports quarterly. The most recent call on file is dated August 5, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

NOVOB

Exchange

CPSE

Country

DK

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

74

First call

January 14, 2020

Most recent

August 5, 2026

Reporting cadence

quarterly